•    

All fields are required.

Close Appointment form

Management Team

Improving patient outcomes with innovative drug therapies.

Stuart Paul

President and Chief Executive Officer

Stuart Paul has served as our President & Chief Executive Officer and a member of Rockwell Medical’s Board of Directors since September 4, 2018.

Mr. Paul has significant operating experience in the healthcare industry, with a successful track record of implementing commercialization strategies both domestically and internationally throughout his 25-year career. Previously, Mr. Paul served as Corporate Officer and Vice President of Abbott Laboratories, where he facilitated integration of the Alere acquisition, while leading its largest global business unit with $600 million of revenues. From 2015 to 2017, Mr. Paul served as the Vice President and General Manager of Quest Diagnostics’ U.S. East Region, where he led the turnaround of the company’s laboratories, patient services and the commercial business.

From 2007 to 2013, Mr. Paul worked at Gambro AB, where he was responsible for leading and profitably expanding a variety of businesses, including its Asia-Pacific and Americas Renal therapeutics businesses. Following the successful sale of Gambro AB to Baxter International, Mr. Paul led the integration of the combined Baxter-Gambro Renal business in Latin America, driving further synergies, revenue and profit growth.

Mr. Paul received his BS degree in chemistry from Duke University and his master’s in marketing and finance from the Kellogg School of Management at Northwestern University.

Angus Smith

Chief Financial Officer

Angus Smith has served as our Chief Financial Officer since November 2018 and is responsible for overseeing all financial operations and investor relations for Rockwell Medical.

From 2014 to 2018, Mr. Smith worked at Pernix Therapeutics, where he most recently served as Senior Vice President, Chief Business Officer and Principal Financial Officer. Prior to this role, he served as both Vice President of Business Development and Strategic Planning, and Vice President of Mergers & Acquisitions and Corporate Finance.

Mr. Smith started his career in healthcare investment banking working for both Cantor Fitzgerald and Gleacher & Company. During his nearly decade-long tenure, Mr. Smith focused on providing strategic and financial advice to specialty pharmaceutical and healthcare companies. Mr. Smith is a seasoned professional with expertise in debt and equity financings, mergers and acquisitions, licensing agreements, joint ventures and strategic partnerships.

Dr. Ajay Gupta, M.D.

Chief Scientific Officer

Dr. Ajay Gupta, M.D., has served as our Chief Scientific Officer for the Company since June 2009.

Before joining the Company, Dr. Gupta spent seven years as an Associate Professor of Medicine at UCLA and the Charles Drew University Schools of Medicine, where he had an active nephrology practice. Prior to that, Dr. Gupta served on the faculties of Washington University at St. Louis, State University of New York at Syracuse, University of Alabama at Birmingham and Henry Ford Hospital, Detroit, MI. Dr. Gupta maintains a nephrology practice and is a volunteer faculty member in the Division of Nephrology at University of California at Irvine.

Dr. Gupta is the inventor of delivering soluble ferric pyrophosphate parenterally including by slow continuous intravenous infusion, via the dialysate in hemodialysis and peritoneal dialysis patients, and as an additive to parenteral nutrition admixtures. Dr. Gupta is the inventor of Triferic (Ferric Pyrophosphate Citrate), our FDA-approved iron maintenance therapy drug for dialysis patients. He has several other patents for drugs, medical devices and diagnostic tests.

Dr. Gupta received a MBBS and completed his residency in Internal Medicine at AII India Institute of Medical Sciences, New Delhi, a clinical fellowship in Nephrology from Wayne State University, Detroit, MI and a research fellowship in Nephrology from Washington University at St. Louis. In addition, he is the Founder of the Indian Society for Bone and Mineral Research.

Dr. Raymond D. Pratt, M.D.

Chief Medical Officer

Dr. Raymond D. Pratt, M.D., has served as our Chief Medical Officer since April 2012.

From 2003 to 2010, Dr. Pratt worked at Shire, PLLC, where he served in various roles including Vice President of Research & Development and as the Scientific Leader in its Emerging Business and Renal Business Units. Previous roles at Shire, PLLC included Vice President of Global Clinical Medicine and Global Clinical Affairs and Head of U.S. Clinical Development. While at Shire, Dr. Pratt was instrumental in the FDA approval of Fosrenol ESRD indication and CKD non-dialysis indication in the European Union and United States. He has managed 10 different drugs through all stages of global development for renal and other indications and has extensive experience appearing before the FDA.

Prior to Shire, PLLC, Dr. Pratt was Senior Director of Clinical Research and Development and Head of Central Nervous System and Internal Medicine Clinical Development at Eisai Medical Research. He also previously served as an Assistant Professor at John Hopkins University and Cornell Medical College in the Department of Medicine and Nephrology.

Dr. Pratt received his M.D. from the University of Illinois College of Medicine and completed his nephrology fellowship at the Walter Reed Army Medical Center, where he practiced nephrology and served as the Assistant Chief of Nephrology Services and Director of Dialysis Services.

Jim McCarthy

Senior Vice President of Business & Corporate Development

Jim McCarthy has served as our Senior Vice President of Business & Corporate Development since September 2018.

Mr. McCarthy is a seasoned business development executive with more than three decades of experience in the life sciences industry, including a 25-year career with Bristol-Myers Squibb. He has served in numerous roles assisting small and emerging life science companies in a wide-range of therapeutic areas with strategic and commercial planning, venture financing, commercial initiatives and deal support on a global basis. In addition, he has significant domestic and international corporate business development experience and has executed a broad range of transactions including licensing deals, strategic alliances and acquisitions.

Mr. McCarthy has also held leading roles in the Licensing Executive Society as Chair of the Life Sciences Sector with the Licensing Executive Society International Life Sciences Leadership Committee. He also is a recipient of the Licensing Executive Society “President’s Award.”

Mr. McCarthy received his BS in physical therapy from SUNY Upstate Medical Center and his MBA from Indiana University. He is also a recipient of the Certified Licensing Professional designation and is a U.S. Army Vietnam infantry veteran.

Charlie Shiner

Vice President of Marketing

Charlie Shiner has served as our Vice President of Marketing since joining the company in December 2018.

Mr. Shiner is an accomplished brand marketing professional with a successful record of driving brand and franchise growth for healthcare and pharmaceutical companies, having served most recently as the marketing franchise leader for Otsuka Pharmaceuticals renal portfolio, where he was instrumental in the launch of Jynarque. Previously, he also held the roles of Director and Senior Product Manager for Digital Marketing at Otsuka, where he was responsible for the digital marketing of cardio-renal products across professional and consumer channels.

Earlier in his career, Mr. Shiner spent more than a decade at Pfizer, where he identified and executed strategic opportunities for Pfizer’s clinical treatments within hospital accounts across the U.S.

Mr. Shiner received his BA from the University of California, Riverside, and his MBA from Northern Illinois University.

Anne Boardman

Vice President of Strategic Accounts

Anne Boardman has served as our Vice President of Strategic Accounts since joining the company in October 2018.

Ms. Boardman’s experience includes more than 30 years in renal, biotech and medical sales, sales management and large corporate account management. Additionally, Ms. Boardman has significant experience in the renal space, with a strong understanding of the reimbursement landscape. Prior to joining Rockwell Medical, Ms. Boardman served as Director of Integrated Healthcare and Vice President of Strategic Accounts at Gambro AB.

Earlier in her career, Ms. Boardman worked at a variety of specialty pharmaceutical and healthcare companies including Watson Nephrology, Genzyme Therapeutics and OrthoBiotech.

Ms. Boardman received her BS from Rollins College.

Michael DeYoung

Vice President of Operations

Michael DeYoung has served as our Vice President of Operations since December 2018. Mr. DeYoung is responsible for leading Rockwell Medical’s Operations team, where he oversees manufacturing operations, logistics and company-wide strategy deployment, specifically for the launch of Triferic® in the U.S. and globally.

Mr. DeYoung’s experience includes more than 25 years in operations and finance. Before joining Rockwell Medical, he served as Chief Financial Officer of ZDHF Holdings, and as the Group Director of Moog Medical Device Group, where he was responsible for finance, human resources and IT operations, and played a key role in the turnaround of the division.

Mr. DeYoung also worked at Gambro AB, where he led operational initiatives contributing to the successful sale of the company to Baxter International and was responsible for the full integration of the Baxter and Gambro renal operations in Latin America.

Mr. DeYoung received his BS from Western Michigan University and his Master’s in accounting from Walsh College.